pre-IPO PHARMA

COMPANY OVERVIEW

TeneoBio, Inc. is a biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAbs™), for the treatments of cancer, autoimmunity, and infectious diseases. TeneoBio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. TeneoSeek rapidly identifies large numbers of unique binding molecules specific for therapeutic targets of interest. Versatile antibody variable domains (UniDabs™) derived from UniAbs™ can be assembled into multi-specific and multivalent therapeutic proteins, surpassing limitations of conventional antibody therapeutics. TeneoBio’s “plug-and-play” T-cell engaging platform includes a diverse set of anti-CD3 antibodies for therapeutics with optimal efficacy and reduced toxicity.


LOCATION

  • Menlo Park, CA, USA

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Infectious Disease
  • Oncology

  • WEBSITE

    https://www.teneobio.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    lightspeed-venture-partners sutter-hill-ventures


    PRESS RELEASES


    Oct 27, 2021

    Newly-Formed Ancora Biotech Will Continue Operations of Teneobio Spin-offs After Successful Acquisition of Teneobio by Amgen


    Oct 19, 2021

    Amgen Successfully Completes Acquisition Of Teneobio, Inc.


    Jul 27, 2021

    Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments


    Apr 5, 2021

    Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL


    Apr 2, 2020

    Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma


    For More Press Releases


    Google Analytics Alternative